Suchergebnisse - "Spinelli, Francesca Romana"

PubPharm (8)

1

Development of Systemic Autoimmune Diseases in Healthy Subjects Persistently Positive for Antiphospholipid Antibodies : Long-Term Follow-Up Study

enthalten in: Biomolecules | 2022

von Ceccarelli, F. | Natalucci, F. | Olivieri, G. | +8

2

Anti-polysaccharide and anti-diphtheria protective antibodies after 13-valent pneumococcal conjugate vaccination in rheumatoid arthritis patients under immunosuppressive therapy

enthalten in: Clinical immunology (Orlando, Fla.) | 2018

von Caporuscio, S. | Ieraci, R. | Valesini, G. | +19

3

Anti-therapeutic antibodies and their clinical impact in patients treated with the TNF antagonist adalimumab

enthalten in: Cytokine | 2017

von Cludts, I. | Spinelli, F. | Morello, F. | +3

ReprintIn: Cytokine. 2018 Jan;101:70-77. - PMID 29174881

4

Decrease of asymmetric dimethyl arginine after anti-TNF therapy in patients with rheumatoid arthritis

enthalten in: Drug development research | 2014

von Spinelli, F. | Di Franco, M. | Metere, A. | +4

5

Biological drug treatment of rheumatoid arthritis and spondyloarthritis : effects on QT interval and QT dispersion

enthalten in: The Journal of rheumatology | 2012

von DI Franco, M. | Paradiso, M. | Ceccarelli, F. | +4

6

Neurocognitive dysfunction in systemic lupus erythematosus : association with antiphospholipid antibodies, disease activity and chronic damage

enthalten in: PloS one | 2012

von Conti, F. | Alessandri, C. | Perricone, C. | +8

7

Uveitis following the use of tumor necrosis factor alpha inhibitors : comment on the article by Lim et al

enthalten in: Arthritis and rheumatism | 2008

von Scrivo, R. | Spadaro, A. | Spinelli, F. | +1

CommentOn: Arthritis Rheum. 2007 Oct;56(10):3248-52. - PMID 17907169

8

Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis : an observational study over a 5-year period

enthalten in: Annals of the rheumatic diseases | 2007

von Conti, F. | Ceccarelli, F. | Marocchi, E. | +5

1
[1]